The approval means an additional indication for osimertinib (Tagrisso; AstraZeneca) for adult patients who have unresectable ...

Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...

The trial met its primary endpoint, showing a meaningful objective response rate and a tolerable safety profile for ...

Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer ...

The lack of a disease-free survival benefit with adjuvant durvalumab in early-stage resected non-small cell lung cancer in ...

The BR.31 trial found that adjuvant durvalumab did not improve disease-free survival in patients with non-small cell lung ...

Patients with NSCLC did not see a disease-free survival benefit with Imfinzi after surgery compared with taking a placebo.

Plinabulin/Docetaxel Combination Demonstrated Favorable Benefit/Risk Ratio over Docetaxel Alone: Significant Improvement in Overall Survival, Progression Free Survival, and Objective Response, with ...

AstraZeneca’s TAGRISSO® (osimertinib)​ has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung ...

THE LATEST findings from the FLOW trial, the first dedicated kidney outcomes trial with semaglutide in patients with Type 2 diabetes (T2D) and chronic kidney disease (CKD), were presented at the ...

Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ETCompany ParticipantsPascal Soriot - Chief ...